Afferon Corporation Enters Exclusive European Development and ...
Afferon Corporation Enters Exclusive European Development and License Agreement with Mundipharma, an Associate of The Purdue Frederick Company ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
BioPortfolio - Mundipharma International Ltd - Profile
Mundipharma International is seeking to license projects at various stages of clinical development in the. following therapeutic areas: ...
http://www.bioportfolio.com/biocorporate/7296-Mundipharma%2B...
|
BioCryst and Mundipharma International Holdings Limited ...
2 Feb 2006 ... "We are delighted to have Mundipharma as our partner for the continued .... license or royalty payments being received by BioCryst, ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
BioPortfolio - Mundipharma Research Limited
2 Oct 2008 ... is granted a worldwide exclusive license for the research. ... and Mundipharma International Corporation Limited, today announced that they ...
http://www.bioportfolio.com/search/Mundipharma_Research_Limi...
|
BioCryst Pharmacueticals - structure based drug design and ...
In February 2006, BioCryst entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization ...
http://www.biocryst.com/alliances.htm...
|
Infinity Announces Global Strategic Alliance With Purdue Pharma ...
Finally, under the alliance, Infinity grants to Mundipharma an option, on set terms, to participate in programs that Infinity may in-license during the term
...
http://biz.yahoo.com/pz/081120/155108.html...
|
office of biomedicalrev.indd
economics, the license agree-. ment between BioCryst and. Mundipharma has the poten-. tial to generate $190 million. plus royalties on product sales. ...
http://www.aecom.yu.edu/uploadedFiles/Biotechnology/officeof...
|
Summary of INFINITY PHARMACEUTICALS, INC. - Yahoo! Finance
During the Funded Research Period, Mundipharma also has an option to obtain ... prescribed percentage of the up-front license fee or other acquisition cost, ...
http://biz.yahoo.com/e/081120/infi8-k.html...
|
Shionogi & Co., Ltd. Launches Cancer Pain Analgesic OxiNorm Powder ...
Licensed from Mundipharma, OxiNorm powder 0.5% is an immediate-release powder ... also under license from Mundipharma, which Shionogi launched in July 2003.
...
http://www.biospace.com/news_story.aspx?NewsEntityId=44799...
|
The Effect of Ethanol on the Release of Opioids from Oral ...
Walden/at/mundipharma-rd.eu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24...
|
